The term ‘cutaneous lupus erythematosus’ (CLE) comprises several related autoimmune skin disorders, defined as ‘specific’ skin manifestations of lupus erythematosus (LE). The spectrum of clinical presentation of CLE is wide, reaching from mild erythema to disseminated scarring skin lesions. There is increasing knowledge concerning the pathogenesis of LE skin lesions and it has been shown that a complex network of cutaneous cytokines, chemokines and adhesion molecules orchestrate and promote tissue injury observed in LE skin lesions. However, a complete understanding of the diverse pathophysiological mechanisms in the different CLE subsets does not exist. Here we review the main pathological features described in CLE patients against the background of the clinical diversity of different CLE subtypes. Lupus (2010) 19, 1020—1028.
Sontheimer RDThe lexicon of cutaneous lupus erythematosus- a review and personal perspective on the nomenclature and classification of the cutaneous manifestations of lupus erythematosus. Lupus1997; 6: 84-95.
2.
David-Bajar KM, Bennion SD, DeSpain JD, Golitz LE, Lee LAClinical, histologic, and immunofluorescent distinctions between subacute cutaneous lupus erythematosus and discoid lupus erythematosus. J Invest Dermatol1992; 99: 251-257.
3.
Wenzel J., Bauer R., Bieber T., Bohm I.Autoantibodies in patients with Lupus erythematosus: spectrum and frequencies . Dermatology2000; 201: 282-283.
4.
Kuhn A., Richter-Hintz D., Oslislo C., Ruzicka T., Megahed M., Lehmann P.Lupus erythematosus tumidus-a neglected subset of cutaneous Lupus erythematosus: report of 40 cases. Arch Dermatol2000; 136: 1033-1041.
5.
Kuhn A., Sonntag M., Ruzicka T., Lehmann P., Megahed M.Histopathologic findings in lupus erythematosus tumidus: review of 80 patients . J Am Acad Dermatol2003; 48: 901-908.
6.
Crowson AN, Magro C.The cutaneous pathology of lupus erythematosus: a review. J Cutan Pathol2001; 28: 1-23.
7.
Jerdan MS, Hood AF, Moore GW, Callen JPHistopathologic comparison of the subsets of lupus erythematosus. Arch Dermatol1990; 126: 52-55.
Wenzel J., Proelss J., Wiechert A., Zahn S., Bieber T., Tuting T.CXCR3-mediated recruitment of cytotoxic lymphocytes in lupus erythematosus profundus. J Am Acad Dermatol2007; 56: 648-650.
10.
Hedrich CM, Fiebig B., Hauck FH, et al. Chilblain lupus erythematosus-a review of literature. Clin Rheumatol2008; 27: 949-954.
11.
Su WP, Perniciaro C., Rogers 3rd RS, White Jr JWChilblain lupus erythematosus (lupus pernio): clinical review of the Mayo Clinic experience and proposal of diagnostic criteria. Cutis1994; 54: 395-399.
12.
Stetson DB, Ko JS, Heidmann T., Medzhitov R.Trex1 prevents cell-intrinsic initiation of autoimmunity. Cell2008; 134: 587-598.
13.
Lee-Kirsch MA, Chowdhury D., Harvey S., et al. A mutation in TREX1 that impairs susceptibility to granzyme A-mediated cell death underlies familial chilblain lupus. J Mol Med2007; 85: 531-537.
14.
Fischer GF, Pickl WF, Fae I., Anegg B., Milota S., Volc-Platzer B.Association between chronic cutaneous lupus erythematosus and HLA class II alleles. Hum Immunol1994; 41: 280-284.
15.
Werth VP, Zhang W., Dortzbach K., Sullivan K.Association of a promoter polymorphism of tumor necrosis factor-alpha with subacute cutaneous lupus erythematosus and distinct photoregulation of transcription . J Invest Dermatol2000; 115: 726-730.
16.
Bielsa I., Herrero C., Ercilla G., et al. Immunogenetic findings in cutaneous lupus erythematosus. J Am Acad Dermatol1991; 25(2 Pt 1): 251-257.
Osmola A., Namysl J., Jagodzinski PP, Prokop J.Genetic background of cutaneous forms of lupus erythematosus: update on current evidence. J Appl Genet2004; 45: 77-86.
19.
Lee HJ, Sinha AACutaneous lupus erythematosus: understanding of clinical features, genetic basis, and pathobiology of disease guides therapeutic strategies. Autoimmunity2006; 39: 433-444.
20.
Pickering MC , Fischer S., Lewis MR, Walport MJ, Botto M., Cook HTUltraviolet-radiation-induced keratinocyte apoptosis in C1q-deficient mice. J Invest Dermatol2001; 117: 52-58.
21.
Werth VPCutaneous lupus: insights into pathogenesis and disease classification. Bull NYU Hosp Jt Dis2007; 65: 200-204.
22.
Nousari HC, Kimyai-Asadi A., Provost TTGeneralized lupus erythematosus profundus in a patient with genetic partial deficiency of C4. J Am Acad Dermatol1999; 41(2 Pt 2): 362-364.
23.
Lee-Kirsch MA, Gong M., Schulz H., et al. Familial chilblain lupus, a monogenic form of cutaneous lupus erythematosus, maps to chromosome 3p. Am J Hum Genet2006; 79: 731-737.
24.
Ueki H.Koebner phenomenon in lupus erythematosus with special consideration of clinical findings. Autoimmun Rev2005; 4: 219-223.
25.
Wenzel J., Tuting T.Identification of type I interferon-associated inflammation in the pathogenesis of cutaneous lupus erythematosus opens up options for novel therapeutic approaches . Exp Dermatol2007; 16: 454-463.
26.
Kuhn A., Krammer PH, Kolb-Bachofen V.Pathophysiology of cutaneous lupus erythematosus-novel aspects. Rheumatology (Oxford)2006; 45(Suppl 3): iii14-16.
27.
Kuhn A., Beissert S.Photosensitivity in lupus erythematosus. Autoimmunity2005; 38: 519-529.
28.
Hawk JLSunlight and health. Not all sunlight is dangerous, just ultraviolet radiation . BMJ1999; 319(7216): 1066-1067.
29.
Barkauskaite V., Ek M., Popovic K., Harris HE, Wahren-Herlenius M., Nyberg F.Translocation of the novel cytokine HMGB1 to the cytoplasm and extracellular space coincides with the peak of clinical activity in experimentally UV-induced lesions of cutaneous lupus erythematosus. Lupus2007; 16: 794-802.
30.
Kuhn A., Herrmann M., Kleber S., et al. Accumulation of apoptotic cells in the epidermis of patients with cutaneous lupus erythematosus after ultraviolet irradiation. Arthritis Rheum2006; 54: 939-950.
31.
Casciola-Rosen LA, Anhalt G., Rosen A.Autoantigens targeted in systemic lupus erythematosus are clustered in two populations of surface structures on apoptotic keratinocytes . J Exp Med1994; 179: 1317-1330.
32.
Wenzel J., Gerdsen R., Uerlich M., Bauer R., Bieber T., Boehm I.Antibodies targeting extractable nuclear antigens: historical development and current knowledge. Br J Dermatol2001; 145: 859-867.
33.
Wenzel J., Bauer R., Bieber T., Boehm I.Discoid and subacute cutaneous lupus erythematosus: detection of differences in peripheral lymphocyte numbers. Acta Derm Venereol2000; 80: 456.
34.
Sontheimer RD, Maddison PJ, Reichlin M., Jordon RE, Stastny P., Gilliam JNSerologic and HLA associations in subacute cutaneous lupus erythematosus, a clinical subset of lupus erythematosus. Ann Intern Med1982; 97: 664-671.
35.
Sontheimer RDPhotoimmunology of lupus erythematosus and dermatomyositis: a speculative review. Photochem Photobiol1996; 63: 583-594.
36.
Oke V., Vassilaki I., Espinosa A., et al. High Ro52 expression in spontaneous and UV-induced cutaneous inflammation. J Invest Dermatol2009; 129: 2000-2010.
37.
Espinosa A. , Dardalhon V., Brauner S., et al. Loss of the lupus autoantigen Ro52/Trim21 induces tissue inflammation and systemic autoimmunity by disregulating the IL-23-Th17 pathway. J Exp Med2009; 206: 1661-1671.
38.
Fritsch C., Hoebeke J., Dali H., et al. 52-kDa Ro/SSA epitopes preferentially recognized by antibodies from mothers of children with neonatal lupus and congenital heart block. Arthritis Res Ther2006; 8: R4.
Dall’era MC, Cardarelli PM, Preston BT, Witte A., Davis Jr JCType I interferon correlates with serological and clinical manifestations of SLE. Ann Rheum Dis2005; 64: 1692-1697.
41.
Ronnblom L. , Eloranta ML, Alm GVThe type I interferon system in systemic lupus erythematosus. Arthritis Rheum2006; 54: 408-420.
42.
Arrue I., Saiz A, Ortiz, Romero PL, Rodriguez-Peralto JLLupus-like reaction to interferon at the injection site: report of five cases . J Cutan Pathol2007; 34(Suppl 1): 18-21.
43.
Conroy M., Sewell L., Miller OF, Ferringer T.Interferon-beta injection site reaction: review of the histology and report of a lupus-like pattern. J Am Acad Dermatol2008; 59(2 Suppl 1): S48-49.
44.
Vallin H., Perers A., Alm GV, Ronnblom L. Anti-double-stranded DNA antibodies and immunostimulatory plasmid DNA in combination mimic the endogenous IFN-alpha inducer in systemic lupus erythematosus. J Immunol1999; 163(11): 6306-6313.
45.
Lovgren T., Eloranta ML, Bave U., Alm GV, Ronnblom L.Induction of interferon-alpha production in plasmacytoid dendritic cells by immune complexes containing nucleic acid released by necrotic or late apoptotic cells and lupus IgG. Arthritis Rheum2004; 50: 1861-1872.
46.
Lovgren T., Eloranta ML, Kastner B, Wahren, Herlenius M., Alm GV, Ronnblom L.Induction of interferon-alpha by immune complexes or liposomes containing systemic lupus erythematosus autoantigen- and Sjogren’s syndrome autoantigen-associated RNA. Arthritis Rheum2006; 54: 1917-1927.
47.
Barrat FJ, Meeker T., Gregorio J., et al. Nucleic acids of mammalian origin can act as endogenous ligands for Toll-like receptors and may promote systemic lupus erythematosus. J Exp Med2005; 202: 1131-1139.
Means TK, Latz E., Hayashi F., Murali MR, Golenbock DT, Luster ADHuman lupus autoantibody-DNA complexes activate DCs through cooperation of CD32 and TLR9. J Clin Invest2005; 115: 407-417.
50.
Gaipl US, Voll RE, Sheriff A., Franz S., Kalden JR, Herrmann M.Impaired clearance of dying cells in systemic lupus erythematosus. Autoimmun Rev2005; 4: 189-194.
51.
Herrmann M. , Winkler T., Gaipl U., Lorenz H., Geiler T., Kalden JREtiopathogenesis of systemic lupus erythematosus . Int Arch Allergy Immunol2000; 123: 28-35.
52.
Wenzel J., Bauer R., Bieber T., Boehm I.Presence of antinuclear antibodies in patients with lupus erythematosus is correlated with diminished T-helper cells. Br J Dermatol2000; 143: 1100-1101.
53.
Fah J., Pavlovic J., Burg G.Expression of MxA protein in inflammatory dermatoses. J Histochem Cytochem1995; 43: 47-52.
54.
Blomberg S. , Eloranta ML, Cederblad B., Nordlin K., Alm GV, Ronnblom L.Presence of cutaneous interferon-alpha producing cells in patients with systemic lupus erythematosus. Lupus2001; 10: 484-490.
55.
Farkas L., Beiske K., Lund-Johansen F., Brandtzaeg P., Jahnsen FLPlasmacytoid dendritic cells (natural interferon-alpha/beta-producing cells) accumulate in cutaneous lupus erythematosus lesions. Am J Pathol2001; 159: 237-243.
56.
McNiff JM, Kaplan DHPlasmacytoid dendritic cells are present in cutaneous dermatomyositis lesions in a pattern distinct from lupus erythematosus . J Cutan Pathol2008; 35: 452-456.
57.
Obermoser G. , Schwingshackl P., Weber F., et al. Recruitment of plasmacytoid dendritic cells in ultraviolet irradiation-induced lupus erythematosus tumidus. Br J Dermatol2009; 160: 197-200.
58.
Wenzel J., Uerlich M., Worrenkamper E., Freutel S., Bieber T., Tuting T.Scarring skin lesions of discoid lupus erythematosus are characterized by high numbers of skin-homing cytotoxic lymphocytes associated with strong expression of the type I interferon-induced protein MxA. Br J Dermatol2005; 153: 1011-1015.
59.
Meller S., Winterberg F., Gilliet M., et al. Ultraviolet radiation-induced injury, chemokines, and leukocyte recruitment: An amplification cycle triggering cutaneous lupus erythematosus . Arthritis Rheum2005; 52: 1504-1516.
60.
Wenzel J., Worenkamper E., Freutel S., et al. Enhanced type I interferon signalling promotes Th1-biased inflammation in cutaneous lupus erythematosus. J Pathol2005; 205: 435-442.
61.
Robak E., Sysa-Jedrzejewska A., Dziankowska B., Torzecka D., Chojnowski K., Robak T.Association of interferon gamma, tumor necrosis factor alpha and interleukin 6 serum levels with systemic lupus erythematosus activity. Arch Immunol Ther Exp (Warsz)1998; 46: 375-380.
62.
Svenungsson E. , Gunnarsson I., Fei GZ, Lundberg IE, Klareskog L., Frostegard J.Elevated triglycerides and low levels of high-density lipoprotein as markers of disease activity in association with up-regulation of the tumor necrosis factor alpha/tumor necrosis factor receptor system in systemic lupus erythematosus. Arthritis Rheum2003; 48: 2533-2540.
63.
Aringer M., Feierl E., Steiner G., et al. Increased bioactive TNF in human systemic lupus erythematosus: associations with cell death. Lupus2002; 11: 102-108.
64.
Malide D., Russo P., Bendayan M.Presence of tumor necrosis factor alpha and interleukin-6 in renal mesangial cells of lupus nephritis patients. Hum Pathol1995; 26: 558-564.
65.
Zampieri S. , Alaibac M., Iaccarino L., et al. Tumour necrosis factor alpha is expressed in refractory skin lesions from patients with subacute cutaneous lupus erythematosus . Ann Rheum Dis2006; 65: 545-548.
66.
Wenzel J., Tuting T.An IFN-associated cytotoxic cellular immune response against viral, self-, or tumor antigens is a common pathogenetic feature in ‘interface dermatitis,’J Invest Dermatol2008; 128(10): 2392-2402.
67.
Wang D., Drenker M., Eiz-Vesper B., Werfel T., Wittmann M.Evidence for a pathogenetic role of interleukin-18 in cutaneous lupus erythematosus . Arthritis Rheum2008; 58: 3205-3215.
68.
Alecu M., Coman G., Alecu S.Serological levels of apoptotic bodies, sFAS and TNF in lupus erythematosus . Rom J Intern Med2000; 38-39: 83-88.
69.
Maczynska I. , Millo B., Ratajczak-Stefanska V., et al. Proinflammatory cytokine (IL-1beta, IL-6, IL-12, IL-18 and TNF-alpha) levels in sera of patients with subacute cutaneous lupus erythematosus (SCLE). Immunol Lett2006; 102: 79-82.
Sontheimer RDSubacute cutaneous lupus erythematosus: 25-year evolution of a prototypic subset (subphenotype) of lupus erythematosus defined by characteristic cutaneous, pathological, immunological, and genetic findings . Autoimmun Rev2005; 4: 253-263.
72.
Fautrel B., Foltz V., Frances C., Bourgeois P., Rozenberg S.Regression of subacute cutaneous lupus erythematosus in a patient with rheumatoid arthritis treated with a biologic tumor necrosis factor alpha-blocking agent: comment on the article by Pisetsky and the letter from Aringer et al. Arthritis Rheum2002; 46: 1408-1409.
73.
Aringer M., Smolen JSEfficacy and safety of TNF-blocker therapy in systemic lupus erythematosus . Expert Opin Drug Saf2008; 7: 411-419.
74.
Ramos-Casals M., Brito-Zeron P., Soto MJ, Cuadrado MJ, Khamashta MAAutoimmune diseases induced by TNF-targeted therapies. Best Pract Res Clin Rheumatol2008 ; 22: 847-861.
75.
Vabre-Latre CM, Bayle P., Marguery MC, Gadroy A., Durand D., Bazex J.Worsening of subacute lupus erythematosus induced by infliximab. Ann Dermatol Venereol2005; 132: 349-353.
76.
Sohl S., Renner R., Winter U., et al. Drug-induced lupus erythematosus tumidus during treatment with adalimumab. Hautarzt2009; 60: 826-829.
77.
Lee HM, Mima T., Sugino H., et al. Interactions among type I and II interferon, tumor necrosis factor, and beta-estradiol in the regulation of immune response-related gene expressions in systemic lupus erythematosus. Arthritis Res Ther2009; 11: R1.
78.
Gutzmer R., Langer K., Mommert S., Wittmann M., Kapp A., Werfel T.Human dendritic cells express the IL-18R and are chemoattracted to IL-18. J Immunol2003; 171: 6363-6371.
79.
Kanda N., Shimizu T., Tada Y., Watanabe S.IL-18 enhances IFNgamma-induced production of CXCL9, CXCL10, and CXCL11 in human keratinocytes. Eur J Immunol2007; 37: 338-350.
80.
Park MC, Park YB, Lee SKElevated interleukin-18 levels correlated with disease activity in systemic lupus erythematosus. Clin Rheumatol2004; 23: 225-229.
81.
Lin YJ, Wan L., Lee CC, et al. Disease association of the interleukin-18 promoter polymorphisms in Taiwan Chinese systemic lupus erythematosus patients. Genes Immun2007; 8: 302-307.
82.
Kuhn A., Beissert S., Krammer PHCD4+CD25+ regulatory T cells in human lupus erythematosus. Arch Dermatol Res2009; 301: 71-81.
83.
Miyara M., Amoura Z., Parizot C., et al. Global natural regulatory T cell depletion in active systemic lupus erythematosus. J Immunol2005; 175: 8392-8400.
84.
Franz B., Fritzsching B., Riehl A., et al. Low number of regulatory T cells in skin lesions of patients with cutaneous lupus erythematosus. Arthritis Rheum2007; 56: 1910-1920.
85.
Wenzel J., Henze S., Worenkamper E., et al. Role of the chemokine receptor CCR4 and its ligand thymus- and activation-regulated chemokine/CCL17 for lymphocyte recruitment in cutaneous lupus erythematosus. J Invest Dermatol2005 ; 124: 1241-1248.
86.
Lehtinen DA , Harvey S., Mulcahy MJ, Hollis T., Perrino FWThe TREX1 double-stranded DNA degradation activity is defective in dominant mutations associated with autoimmune disease . J Biol Chem2008; 283(46): 31649-31656.
87.
Lee-Kirsch MA, Gong M., Chowdhury D., et al. Mutations in the gene encoding the 3'-5' DNA exonuclease TREX1 are associated with systemic lupus erythematosus . Nat Genet2007; 39: 1065-1067.
88.
Wenzel J., Zahn S., Mikus S., Wiechert A., Bieber T., Tuting T.The expression pattern of interferon-inducible proteins reflects the characteristic histological distribution of infiltrating immune cells in different cutaneous lupus erythematosus subsets. Br J Dermatol2007; 157: 752-757.
89.
Bashir MM, Sharma MR, Werth VPTNF-alpha production in the skin. Arch Dermatol Res2009; 301: 87-91.
